Tildrakizumab, sold under the brand name Ilumya among others, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory...
15 KB (1,506 words) - 05:31, 2 July 2024
into a licensing agreement with Merck & Co. Inc. to acquire rights for Tildrakizumab (MK- 3222) for treatment of chronic plaque psoriasis, in order to further...
17 KB (1,553 words) - 19:38, 29 July 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
22 KB (1,789 words) - 04:29, 16 July 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
31 KB (2,444 words) - 00:18, 6 August 2024
have faster onset of action in treatment of psoriasis than guselkumab, tildrakizumab or risankizumab, which are inhibitors of the p19 subunit of IL-23. However...
20 KB (2,192 words) - 23:02, 27 November 2023
Ixekizumab L04AC14 Sarilumab L04AC15 Sirukumab L04AC16 Guselkumab L04AC17 Tildrakizumab L04AC18 Risankizumab L04AC19 Satralizumab L04AC20 Netakimab L04AC21...
3 KB (367 words) - 15:37, 25 January 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
22 KB (2,510 words) - 04:11, 12 August 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
22 KB (2,581 words) - 20:03, 21 June 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
17 KB (1,245 words) - 04:39, 17 August 2024
Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab†Lebrikizumab Olokizumab†Perakizumab Risankizumab Spesolimab Tildrakizumab Veterinary Lokivetmab...
38 KB (4,304 words) - 10:14, 21 July 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
43 KB (3,662 words) - 19:35, 12 July 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
14 KB (1,037 words) - 04:45, 6 July 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
63 KB (7,473 words) - 02:17, 23 July 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
24 KB (2,070 words) - 07:13, 15 March 2024
Risankizumab Ritlecitinib Rozanolixizumab Sarilumab Satralizumab Siltuximab Siponimod Sirukumab Spesolimab Sutimlimab Tildrakizumab Tofacitinib Upadacitinib...
7 KB (299 words) - 13:45, 27 April 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
14 KB (1,578 words) - 14:00, 26 February 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
45 KB (4,194 words) - 12:36, 2 May 2024
Spasticity in Multiple Sclerosis Monovo Mometasone Psoriasis Ilumetri Tildrakizumab Psoriasis Ebglyss Lebrikizumab Atopic Dermatitis Wynzora Calcipotriol/Betamethasone...
15 KB (1,055 words) - 04:55, 25 May 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
14 KB (1,147 words) - 07:33, 11 August 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
5 KB (272 words) - 03:23, 14 August 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
49 KB (6,005 words) - 16:30, 10 June 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
12 KB (1,289 words) - 19:20, 4 December 2023
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
43 KB (5,000 words) - 13:28, 1 July 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
19 KB (2,293 words) - 11:05, 8 March 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
22 KB (2,786 words) - 05:10, 17 August 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
3 KB (203 words) - 04:43, 15 August 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
40 KB (4,858 words) - 14:50, 21 July 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
16 KB (1,451 words) - 18:24, 2 August 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
20 KB (2,117 words) - 23:53, 11 August 2024
23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27 (interleukin 30) IL-28 Agonists:...
18 KB (1,654 words) - 05:40, 1 July 2024